Aviva India faces $7.5 million fine over fake invoice scheme

British insurer Aviva’s India unit has been ordered to pay $7.5 million in back taxes and penalties after authorities found it engaged in fraudulent practices to evade taxes, according to a February 5 order reviewed by Reuters.

ALSO READ70-hour work week concept is ‘bats**t crazy’, says Veeba founder Viraj Bahl Fake invoices

An investigation revealed that between 2017 and 2023, Aviva India paid approximately $26 million to vendors supposedly providing marketing services. However, authorities found these vendors were merely fronts used to funnel illegal commissions to Aviva’s agents beyond regulatory limits. By using fake invoices and cash payments, Aviva incorrectly claimed tax credits and evaded $5.2 million in taxes.

ALSO READStocks To Watch: From BHEL to Glenmark Pharma- Here’s a list of 10 stocks to track today

After reviewing Aviva’s defence, Joint Tax Commissioner Aditya Singh Yadav concluded the company had deliberately evaded taxes amounting to 326 million rupees ($3.8 million). Following this, Aviva was ordered to pay this amount along with a 100% penalty, bringing the total to 653 million rupees ($7.5 million). The order stated that the vendors were mere “puppets” in Aviva’s scheme to claim bogus tax credits.

In response to the ruling, Aviva India stated that it would contest the decision through an appeal and assured that the order would have no impact on its operations. The company operates in India as a joint venture with Dabur Invest Corp., which owns a 26% stake after Aviva increased its holding from 49% to 74% in 2022. Meanwhile, Dabur has not commented on the issue.

Aviva’s India business reported a profit after tax of only $10 million in the 2023-24 financial year. 

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth